Abstract
The recent emergence of multiple SARS-CoV-2 variants has caused considerable concern due to both reduced vaccine efficacy and escape from neutralizing antibody therapeutics. It is, therefore, paramount to develop therapeutic strategies that inhibit all known and future SARS-CoV-2 variants. Here, we report that all SARS-CoV-2 variants analyzed, including variants of concern (VOC) Alpha, Beta, Gamma, Delta, and Omicron, exhibit enhanced binding affinity to clinical grade and phase 2 tested recombinant human soluble ACE2 (APN01). Importantly, soluble ACE2 neutralized infection of VeroE6 cells and human lung epithelial cells by all current VOC strains with markedly enhanced potency when compared to reference SARS-CoV-2 isolates. Effective inhibition of infections with SARS-CoV-2 variants was validated and confirmed in two independent laboratories. These data show that SARS-CoV-2 variants that have emerged around the world, including current VOC and several variants of interest, can be inhibited by soluble ACE2, providing proof of principle of a pan-SARS-CoV-2 therapeutic.
Keywords: COVID-19; clinical trial; treatment; vaccine.
【저자키워드】 COVID-19, Treatment, clinical trial, vaccine., 【초록키워드】 neutralizing antibody, Efficacy, Vaccine, clinical trial, VoC, Phase 2, SARS-CoV-2 variant, Infection, variants of concern, Delta, omicron, variants, binding affinity, SARS-CoV-2 variants, human lung, therapeutic, Therapeutic strategies, Gamma, Alpha, Beta, epithelial cells, therapeutic strategy, soluble ACE2, strain, epithelial cell, principle, These data, several variants, proof, SARS-CoV-2 isolates, VeroE6 cells, human lung epithelial cells, independent, neutralized, tested, analyzed, develop, caused, inhibit, inhibited, reduced, several variant, VeroE6 cell, 【제목키워드】 ACE2, SARS-CoV-2 variant, clinical,